On April 22, 2026 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, reported that updated clinical data from its Phase 1/2 study of CRB-701, a next generation Nectin-4 ADC, in both head and neck squamous cell carcinoma (HNSCC) and cervical cancer will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, to be held May 29 – June 2 in Chicago, IL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data will include clinical response durability as well as HNSCC patient subgroup analysis. Corbus previously presented dose optimization data from the study, including encouraging efficacy and safety findings, at the 2025 European Society for Medical Oncology Congress (ESMO 2025).

Oral Presentation
A phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical cancer – (Tudor-Eliade Ciuleanu, MD, PhD, Arensia Research Clinic; Dominique Berton, MD, Institut de Cancérologie de l’Ouest; et al)

Presenter: Professor Yohann Loriot, Gustave Roussy (Paris)
Session Date and Time: May 29, 4:57 PM CDT
Session Title: Gynecological Cancer
Abstract #: 5508

Poster Presentation:
A phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and neck squamous cell carcinoma – (Charlene Mantia, MD, Glenn J Hanna, MD; Dana Farber, et al)

Presenter: Charlene Mantia, MD, Dana Farber Cancer Institute (Boston)
Session Date and Time: May 30, 4:30 PM CDT
Session Title: Head and Neck Cancer
Abstract #: 6062
Poster Board: 519

The abstracts will be available on the ASCO (Free ASCO Whitepaper) website on May 21, 2026 at 5:00 p.m. ET.

Corbus expects to initiate a registrational study for CRB-701 in second-line HNSCC in mid-2026.
Corbus also anticipates reporting data with CRB-701 in combination with Keytruda in first-line HNSCC patients in Q4 2026 to support potential further registration-enabling trials.

About CRB-701
CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer. The FDA has granted two Fast Track designations to CRB-701 in HNSCC and cervical cancer. CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China.

(Press release, Corbus Pharmaceuticals, APR 22, 2026, View Source [SID1234664679])

On April 22, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that Cheryl Cox, MHA, Operations Director of the Cell Therapies and Gene Expression Engineering Facility at Moffitt Cancer Center, will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, being held May 6 – 9, 2026, in Dublin, Ireland.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ms. Cox’s presentation, titled "Phase 1 clinical trial of autologous T cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer," will discuss the clinical trial design and objectives, as well as the current status of Anixa’s ongoing Phase 1 clinical trial of lira-cel.

The ISCT 2026 Annual Meeting will bring together thousands of global experts in cell and gene therapy. This event is recognized as the largest conference focused on translating cell and gene therapies from research to clinical practice. The four-day program will feature hundreds of speakers, cutting edge scientific presentations, and interactive sessions covering advances in areas such as gene editing, bioprocessing, and clinical translation, alongside extensive networking opportunities and industry showcases.

About Lira-cel, Anixa’s CAR-T Therapy for Recurrent Ovarian Cancer
Liraltagene autoleucel, or lira-cel, uniquely targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells, but not in healthy tissue. The ongoing Phase 1 trial (ClinicalTrials.gov NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies.

(Press release, Anixa Biosciences, APR 22, 2026, View Source [SID1234664678])

On April 22, 2026 ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), reported the dosing of patients with its first-in-class tetraspecific T-cell engager, MDX2003, for relapsed or refractory B-cell lymphoma. This multispecific antibody targets two proteins found on the surface of B-cell malignancies, CD19 and CD20, along with the CD3 and CD28 co-stimulatory T-cell activators to sustain T cell killing of these tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The MDX-2003-101 study (NCT07249905) is designed to evaluate the safety, tolerability, pharmacokinetic, and immune activity of MDX2003 in adult patients with various types of B-cell lymphoma. The study includes dose-escalation and dose-expansion phases. B-cell lymphoma, a form of non-Hodgkin lymphoma arising from B lymphocytes, represents the most common lymphoma subtype, accounting for approximately 85% of cases1. Despite available therapies, an estimated 30–40% of patients experience disease relapse, progression, or refractory disease following initial chemoimmunotherapy2.

"This clinical trial represents a significant milestone for ModeX," said Giovanni Abbadessa, M.D., Ph.D., Chief Medical Officer of ModeX Therapeutics. "MDX2003 is designed to address limitations of current T‑cell-engagers by combining dual tumor antigen targeting with optimized T‑cell activation. This first‑in‑human study will allow us to assess safety and biologic activity in patients with advanced B‑cell lymphoma."

Preclinical proof-of-concept data, along with analyses supporting clinical dose selection, were presented in poster presentations at the 2025 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and ESMO (Free ESMO Whitepaper) Targeted Anticancer Therapies Congress 2026.

"MDX2003 takes advantage of our proprietary multispecific antibody design to optimize tumor killing and address the problem of immune escape in the treatment of lymphoma," said Phillip Frost, M.D., Chairman and CEO of OPKO Health, and Gary Nabel, M.D., Ph.D., President and CEO of ModeX and Chief Innovation Officer of OPKO Health. "This study will define dosing and treatment regimens for future efficacy trials."

About MDX2003

MDX2003 is a novel tetraspecific T-cell engager targeting CD19 and CD20 on B cells and CD3 and CD28 on T cells. This dual B-cell targeting strategy is intended to mitigate the impact of tumor antigen loss, while CD3/CD28 co-stimulation aims to promote robust T-cell activation, survival, and sustained cytotoxic activity. Preclinical studies have demonstrated potent anti-tumor activity and balanced T-cell activation, supporting advancement into clinical evaluation.

(Press release, Opko Health, APR 22, 2026, View Source [SID1234664677])

On April 22, 2026 Amplia Therapeutics limited (ASX:ATX | OTCQB:INNMF), ("Amplia" or the "Company") reported that an oral presentation highlighting mature data from the Company’s ACCENT trial in metastatic pancreatic cancer is being delivered today at the annual meeting of the AACR (Free AACR Whitepaper). The presentation includes more detailed analysis of the recently reported data from the ACCENT study, which is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of- care chemotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation is included as part of a mini-symposium entitled Advances in Precision Oncology being held in the San Diego Convention Center, San Diego USA, and will be delivered by Amplia’s Director of Translational Biology, Dr Terrie-Anne Cock, at 3:44 pm local time. A copy of the slides is included with this announcement.

• Narmafotinib displays a manageable toxicity profile, with no significant tolerability burden over chemotherapy alone
• Independent (central) reading of data identified 5 confirmed Complete Responses (CR’s) from 64 patients, an 8% CR rate compared to a 0.2% rate for chemotherapy alone
• A response rate of 36% is observed (23 of 64 patients); 42% if unconfirmed responses included
• A Disease Control Rate (DCR) of 70% was determined, compared to 50% for chemotherapy alone
• Median overall survival (mOS) was found to be 11.1 months, while median progression-free survival (mPFS) was 7.7 months, both showing improvements of over two months compared to chemotherapy alone
• A trend to improved Overall Survival is observed when comparing Stable Disease, Partial
Response and Complete Response patients
• The combined efficacy data is superior to chemotherapy alone across all measures despite the intermittent narmafotinib dosing schedule employed (12 days of each 28 day treatment cycle)
• Subsequent trials will employ a daily dosing regimen of narmafotinib given the tolerability observed to date, which may lead to improved responses

Dr Chris Burns, CEO and Managing Director of Amplia, commented: "We are excited to present this mature ACCENT data at the AACR (Free AACR Whitepaper) annual meeting. Being able to present the extremely promising clinical responses to colleagues and peers at one of the world’s most prestigious oncology conferences allows us to demonstrate the potential narmafotinib has in the treatment of this terrible disease. We are now focused on building on this promising data with additional clinical studies, including a pivotal study based on the ACCENT trial, as well as combination studies with the exciting new class of drugs called kRAS inhibitors."

(Press release, Amplia Therapeutics, APR 22, 2026, View Source [SID1234664627])

On April 22, 2026 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, reported an abstract has been selected for poster presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place in-person and online from 29 May-2 June 2026 in Chicago, Illinois (United States).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted abstract, titled "Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients," will be presented within the Developmental Therapeutics—Immunotherapy sessions by Professor Martin Forster from the UCL Cancer Institute, UK.

The poster will present cumulative clinical and translational data demonstrating that eftilagimod alfa (efti), an antigen-presenting cell (APC) activator targeting MHC Class II, induces rapid and sustained lymphocyte activation. Across multiple late-stage cancer studies1, immune activation markers were associated with improved overall survival outcomes in patients with metastatic disease, supporting the clinical relevance of eftilagimod alfa’s mechanism of action.

ASCO 2026 Poster Presentation Details

Title: Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients
Poster Session: Developmental Therapeutics—Immunotherapy
Date and Time: 30 May 2026, 1:30 PM-4:30 PM CDT
Poster Board: 359
Abstract #: 2569

About ASCO (Free ASCO Whitepaper) 2026

The ASCO (Free ASCO Whitepaper) Annual Meeting represents the world’s largest gathering of oncology physicians, industry representatives, researchers, patient advocates and investment analysts to discuss cutting-edge clinical research and emerging therapeutics in oncology, and to gain insights to improve cancer care. More than 40,000 attendees from around the world are expected to participate in person and online to stay up to date on the latest advances across all areas of cancer research and to hear real-time insights from world-renowned experts. For additional information on the ASCO (Free ASCO Whitepaper) Annual Meeting, please visit www.asco.org.

(Press release, Immutep, APR 22, 2026, View Source [SID1234664625])